Muvon Therapeutics develops an autologous cell‑based platform that isolates, expands, and injects muscle precursor cells to regenerate skeletal muscle tissue. The technology is currently applied to treat female stress urinary incontinence, having completed Phase II clinical trials. By restoring muscle function, the company aims to address high‑unmet‑need conditions caused by muscle damage or degeneration.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Stress urinary incontinence (SUI) in women results from degeneration or damage to skeletal muscle, significantly impacting their quality of life due to loss of bladder control. Current treatments often fail to fully restore muscle function and can have limited long-term effectiveness.
Solution
Muvon Therapeutics is developing personalized regenerative therapies for treating diseases related to skeletal muscle damage or degradation, with an initial focus on female SUI. The therapeutic platform isolates muscle precursor cells (MPCs) from a patient's own tissue, expands these cells in a controlled environment, and then injects them back into the damaged muscle tissue to promote regeneration. This autologous cell therapy aims to repair damaged tissue and increase the regenerative potential of weakened muscles, offering a safe and effective treatment option. The therapy is currently in Phase II clinical development.
Target Audience
The primary target audience is women suffering from stress urinary incontinence (SUI) and healthcare providers specializing in urology and women's health.
Features
- Autologous cell-based therapy using patient's own muscle precursor cells (MPCs)
- Targeted isolation of MPCs from muscle tissue
- Controlled expansion of MPCs in a laboratory setting
- Regeneration of muscle tissue through injection of expanded cells
- Proprietary regenerative platform technology to induce functional skeletal muscle regeneration